LORUS SIGNS VIRULIZIN SUPPLY PACT WITH BIOVECTRA.Lorus Therapeutics Inc. (Lorus), Toronto, a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer, has signed a commercial supply agreement with Diagnostic Chemicals Limited operating as BioVectra dcl (BioVectra) for the commercial manufacture of Virulizin(R). Lorus has successfully completed the technology transfer process to BioVectra, which is critical to the commercialization of Virulizin(R). Moving forward, Lorus will scale up to commercial batch size by the second quarter of 2005. The documentation that supports these activities will be of paramount importance during the US Food and Drug Administration's (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) pre-approval inspection of the full-scale manufacturing site. BioVectra is an FDA-inspected, privately owned, Canadian company located in Charlottetown, PEI. Its 33,500 square foot cGMP manufacturing facility provides technology-based custom manufacturing to a number of large pharmaceutical and biotechnology companies on a global scale. BioVectra's expertise includes preclinical phase I to phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the material, active pharmaceutical ingredients, natural product extraction and purification and advanced intermediates. Virulizin(R) is currently the subject of a fully enrolled global Phase III registration clinical trial for the treatment of advanced pancreatic cancer pancreatic cancer Malignant tumour of the pancreas. Risk factors include smoking, a diet high in fat, exposure to certain industrial products, and diseases such as diabetes and chronic pancreatitis. Pancreatic cancer is more common in men. in combination with gemcitabine. The clinical trial has enrolled more than 400 patients at over 100 oncology centres around the world. The clinical trial results are expected during the second half of 2005. To date, Virulizin(R) has received fast track status, orphan drug orphan drug, drug developed under the U.S. Orphan Drug Act (1983) to treat a disease that affects fewer than 200,000 people in the United States. The orphan drug law offers tax breaks and a seven-year monopoly on drug sales to induce companies to undertake the status and a special protocol assessment from the FDA. "This collaboration represents an excellent fit for BioVectra as Virulizin(R) advances through the regulatory process," said Dr. Tony Lucas, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of BioVectra dcl. "We look forward to a long and mutually rewarding relationship with Lorus." "The signing of this commercial supply agreement with BioVectra is a significant achievement in the commercialization process for Virulizin(R)," said Dr. Jim Wright, CEO of Lorus Therapeutics. "We are pleased to be aligned with BioVectra, a company with extensive experience supplying product to the pharmaceutical and diagnostic industries." For more information, visit http://www.BioVectra.com. About Lorus Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of eight clinical trials in phase II clinical trial Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange Toronto Stock Exchange (TSE) Canada's largest stock exchange, trading approximately 1,200 company stocks and 33 options. under the symbol LOR LOR Letter Of Reprimand (military) LoR Lord of the Rings (J.R.R. Tolkien) LOR Learning Object Repository LOR Linux.Org. , and on the American Stock Exchange American Stock Exchange (AMEX) Stock exchange in the U.S. Originally known as “the Curb,” it began as an outdoor marketplace in New York City c. 1850. It moved indoors to its present location in the Wall Street area in 1921. under the symbol LRP LRP Lipoprotein Receptor-Related Protein LRP Low Density Lipoprotein Receptor-Related Protein LRP Loan Repayment Program LRP Linux Router Project LRP Livestock Risk Protection LRP Laparoscopic Radical Prostatectomy Lrp Leucine-responsive Regulatory Protein . Virulizin(R) is a registered trademark of Lorus Therapeutics Inc. For more information, visit http://www.lorusthera.com or call 416/798-1200 ext. 338. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion